Partnering with University of Toronto’s Data Sciences Institute (DSI) will give OICR researchers access to new funding and collaborations.
OICR is combining forces with another Ontario leader in data science research to help leverage Big Data into new discoveries about cancer.
OICR will be partnering with the Data Sciences Institute (DSI), University of Toronto’s hub for data science research and training.
“Partnering with DSI is a natural step for OICR, which has been a leading data science institute since its inception and has made major contributions in cancer data sharing and analysis,” says Dr. Lincoln Stein, Head of Adaptive Oncology for OICR and Professor of Molecular Genetics at the University of Toronto.
The partnership will allow OICR investigators and students to apply for DSI-sponsored training grants, take part in educational and network opportunities, find new collaborative opportunities and share expertise with other members of the institute.
“We are very excited to have the Ontario Institute for Cancer Research join our growing DSI community,” DSI Director Lisa Strug said in an announcement about the partnership. “By connecting and supporting data science researchers, the DSI advances research and nurtures the next generation of data- and computationally focused researchers.”
DSI faculty includes experts in various disciplines, from environmental sciences to economics, and Stein says adding OICR into the mix increases the chances of making new and exciting discoveries together.
“The greatest breakthroughs in science have come when members from different scientific disciplines meet, compare notes, and have an aha! moment,” Stein says.
OICR’s President and Scientific Director says collaborations like these ensure OICR remains at the forefront of cancer research and care.
“With a shared commitment to maximizing the health and economic benefit of our research for the people of Ontario, this partnership with DSI holds tremendous potential to drive breakthroughs in cancer research that can bring real benefits to those affected by cancer,” says OICR President and Scientific Director, Dr. Laszlo Radvanyi.